Italy organoids and spheroids Market Expected to Reach $36.6 Million by 2032

According to a new report published by Allied Market Research, titled, “Italy organoids and spheroids Market by Type, Method, End User: Opportunity Analysis and Industry Forecast, 2023–2032," The Italy organoids and spheroids market size valued for $13.8 million in 2022 and is estimated to reach $36.6 million by 2032, exhibiting a CAGR of 10.2% from 2023 to 2032. An organoid is an in vitro-produced miniaturized replica of an organ, designed to replicate realistic micro-anatomy. These structures are capable of self-renewal and demonstrate functional traits akin to the original tissue. Organoids are highly complex and are more in vivo-like when compared to spheroids.

Factors that drive the growth of the Italy organoids and spheroids market include surge in R&D activities in cell research by various biotechnology companies, and shift in preference toward organoids 3D cell cultures for cancer research. In addition, rise in technological advancement in 3D spheroids and organoids technologies is anticipated to propel the growth of the Italy organoids and spheroids industry. For instance, Merck KGaA offers the 3dGRO Human iPSC Derived Colon Organoids, a highly characterized cryopreserved human colon intestinal organoids derived from integration-free human induced pluripotent stem cells (iPSCs). Such advanced products available in the market drive the growth.

In addition, the emergence of patient-derived organoids (PDOs) has revolutionized personalized medicine which further drives market growth. PDOs are derived from individual patient tissues and retain the genetic and phenotypic characteristics of the original tumors. They enable testing of various treatments on a patient's own cells, facilitating the identification of tailored therapies and more accurate prediction of treatment outcomes. Furthermore, technological advancements have played a pivotal role in driving the growth and adoption of organoids and spheroids in the market. 

These advancements have not only improved the efficiency and reproducibility of culturing these 3D cell models but also expanded their applications in various research fields. For Instance, Corning Incorporated offers the Corning Matrigel matrix, a natural extracellular matrix (ECM)-based hydrogel, is widely used and referenced in 3D cell culture, in support of organoid and spheroid formation. The need for more convenient, consistent, pre-coated format options has emerged as 3D cell culture models migrate into a high throughput environment. Such features offered by organoids and spheroids support market growth.

By type, the organoids and spheroids market are segmented into organoids and spheroids. The organoids segment is further categorized into neural organoids, hepatic organoids, intestinal organoids, and others. The spheroids segment further segmented into multicellular tumor spheroids, neurospheres, mammospheres, and hepatospheres. The organoids segment accounted for the largest share of the market in 2022 and is expected to register the highest CAGR during the forecast period. The dominance of this segment can be attributed to rise in the adoption of organoids in various applications such as disease modeling, pathogenesis, drug screening, and regenerative medicine. 

In addition, organoids have the ability to replicate the intricate biology of organs and tissues, the advent of patient-derived models, and their broad applicability across various research and industrial sectors further support the segment growth. By method, the market is segmented into extracellular matrix scaffold method, spinning bioreactor method, hanging drop method, low adherent culture plate method, magnetic levitation method and others. The extracellular matrix scaffold method segment exhibited the largest share in 2022 and is also expected to register the highest CAGR during the forecast period. 

This is attributed to the rise in demand for extracellular matrix (ECM) scaffold method as it offers a unique and sophisticated approach to creating 3D cell culture environments. In addition, the potential for personalized medicine and patient-specific therapies has fueled the growth of the extracellular matrix scaffold method segment.

By end user, the market is fragmented into biotechnology and pharmaceutical industries, academic & research institutes, hospitals, and diagnostic centers. Among these, the biotechnology & pharmaceutical industries segment exhibited the highest growth in 2022, and is anticipated to lead during the forecast period, owing to surge in use of organoids for biopharmaceuticals and cancer drug research. In addition, rise in the demand for personalized medicine and precision therapies has grown significantly that supports the segment growth.

KEY FINDINGS OF THE STUDY

• On the basis of type, the organoids segment was largest contributor to the market in 2022.
• On the basis of method, the extracellular matrix scaffold method segment was largest contributor to the market in 2022. 
• On the basis of end user, the biotechnology & pharmaceutical industries segment dominated the market in terms of revenue in 2022.